Several of my patients are having a hard time filling their estradiol patches right now. Not one pharmacy being out for a week. Calling four places, getting a different strength than was prescribed, driving across town, running out before the next box arrives.
So let us go through the explanations people are offering, in order, and then what the evidence actually supports.
Hypothesis one: everyone started using them at once
This one is true, and the numbers are not subtle.
Estradiol patch prescriptions went from about 594,000 in June 2024 to 1.6 million in May 2026 (1). Among women aged 45 to 54, prescribing rose 184 percent, and by February 2026 roughly one in twenty women in that age group had an estrogen prescription (2). Patches now account for a large share of all estrogen prescriptions, and they were never the volume product the supply chain was built around.
The accelerant was regulatory. On November 10, 2025, the FDA announced it was removing the boxed warnings about cardiovascular disease, breast cancer and dementia from menopausal hormone therapy, with Commissioner Marty Makary saying the agency intended to “stop the fear machine steering women away from this life-changing, even lifesaving, treatment” (3). Those warnings had suppressed use for two decades. Pull them off, and a very large number of women who had been told no for years hear a different answer in the same month.
I wrote about that decision when it happened and I thought it was defensible. I did not expect it to empty the shelves.
Hypothesis two: something broke in manufacturing
This one is mostly false, and it is worth saying so clearly because it is the version that frightens people.
There is no recall behind this. No contamination finding, no plant shutdown, no safety problem with the patches that are reaching pharmacies. The FDA’s position, repeated through the summer, is that all the manufacturers are producing at full capacity (4).
What is true is that patches are hard to make more of quickly. A transdermal patch is a drug-in-adhesive matrix that has to deliver a precise dose through skin for three or four days. The production lines are specialized, and companies describe expansion timelines in years rather than months. Add thin generic margins, and nobody is rushing to build a new line for a product that might be a fad.
So: not a manufacturing failure. A manufacturing capacity ceiling, which is a different thing and gets solved on a much slower clock.
Hypothesis three: RFK Jr. and the administration did this
This is the one I keep seeing in comment sections, and the honest answer is more interesting than either the accusation or the denial.
There was no sabotage. Nobody restricted estrogen. If anything, this administration’s FDA pushed hormone therapy harder than any in twenty years, and the demand surge is a direct downstream consequence of that push. You cannot simultaneously argue that they suppressed access and that they promoted the drug into a shortage.
Where policy does have fingerprints is slower and less dramatic. HHS cut roughly 3,500 FDA positions in 2025 as part of a larger restructuring (5). The agency said reviewers and inspectors were protected. Reporting since has described reviewers absorbing administrative work and longer, less predictable timelines. None of that caused the shortage. All of it makes a nimble response harder, and a nimble response is exactly what a demand shock requires.
And there is a specific, consequential decision sitting right in the middle of this.
The part that actually matters: the FDA has not declared a shortage
Pharmacists have been listing estradiol patches as short since January 30, 2026. ASHP’s bulletin has grown to roughly 17 affected packages across five manufacturers, including Dotti, Lyllana, and the Noven, Sandoz, Viatris and Zydus generics (6).
The FDA has acknowledged that women are having trouble and says it is working with manufacturers to expand supply (7). It has not added the patches to its official shortage list.
That gap is not bureaucratic trivia. A formal shortage designation changes what other parties are allowed and incentivized to do. It can ease the path for additional manufacturers, it supports compounding in some circumstances, and it affects how insurers handle a prescription that has to be split across strengths or pharmacies. An Arizona gynecologist, Dr. Suzanne Hackenmiller, started a petition asking for the declaration, and Democratic members of the House have written to the agency asking the same (8).
So the fair summary of the policy question is this. The administration did not cause a shortage by restricting anything. It drove demand deliberately and then declined to use the one administrative tool that would most directly help the women it told to ask for treatment.
Two more explanations worth naming
Fragmentation makes it worse. When a patient cannot get one 0.1 mg patch, the workaround is often two 0.05 mg patches, or a different brand at a different pharmacy. Every one of those workarounds consumes more units of a constrained product and can generate a second copay. Scarcity plus substitution produces more scarcity.
Stockpiling is rational and corrosive. A woman who has been told to ration her patches will fill three months when she can get three months. I do not blame anybody for that. It also means supply reaches fewer people in any given week.
What to do if you are caught in this
First, do not simply stop. Vasomotor symptoms come back fast once estrogen is withdrawn, and the people who suffer most in a shortage are the ones who quietly go without and assume there was no alternative.
There are several, and most of them keep you on transdermal delivery, which matters if the reason you were on a patch in the first place was migraine with aura, a clot history, or anything else that argued against oral estrogen.
Gels and sprays are the closest substitute: EstroGel, Divigel, Evamist. Same route, same avoidance of first-pass liver metabolism, different daily routine. Oral estradiol is reasonable for many women and is widely available and cheap, though it is not the right swap for everyone. A different patch brand or a weekly patch instead of a twice-weekly one is often available when your usual one is not. If your symptoms are limited to vaginal dryness and painful sex, local vaginal estrogen is a different supply chain entirely and is not caught up in this.
Practical things that work: ask the pharmacy to check the strengths they do have rather than just saying no, call independent pharmacies because they order through different channels than the big chains, ask for a 90-day fill when you find stock, and have your clinician send the prescription with the substitution permitted so the pharmacist can act without a second call.
For clinicians
Write the alternative into the prescription up front. A patch prescription with no permitted substitution turns every stockout into a phone call, and in a shortage that is where the days get lost.
Know which of your patients actually need transdermal delivery rather than merely prefer it, because that determines whether oral is an acceptable bridge or a bad idea.
And counsel on the rebound explicitly. A patient who runs out and waits two weeks does not experience that as a supply problem. She experiences it as hormone therapy failing, and some of them do not come back.
The Bottom Line
The estrogen patch shortage is a demand shock, not a manufacturing failure and not a conspiracy.
The FDA removed a twenty-year-old warning, prescriptions nearly tripled in two years, and a small, low-margin, slow-to-expand corner of the generic industry could not absorb it. The policy criticism that holds up is not that anyone blocked access. It is that the agency drove the demand and has still not declared the shortage that would help unlock supply.
If you are affected, you have options, and most of them keep you on the same route of delivery. Call before you run out rather than after.
Related Reading
FDA Removes Black Box Warning From Menopause Hormone Therapy
Menopause Care by Telemedicine: What a Virtual Visit Can and Cannot Do
Perimenopause and Menopause Symptoms and How to Manage Them
Menopause and Sleep: What Is Actually Waking You Up
Vaginal Dryness After Menopause: Why It Doesn’t Go Away
More on Menopause & Women’s Health
Scott Rennie, D.O.
Board Certified in Obesity Medicine and Family Medicine
This blog is for educational purposes only and does not constitute individual medical advice. Always consult your own physician before making changes to your health, medications, or treatment plan.
Sources
- Estrogen patch shortage prompts doctors, lawmakers to seek FDA action. CBS News, September 3, 2026. https://www.cbsnews.com/news/estrogen-patch-shortage-fda-declaration-hormone-replacement-therapy/
- Menopause Estrogen Patches Are in Short Supply. What Are the Alternatives? Healthline, April 15, 2026. https://www.healthline.com/health-news/menopause-estrogen-patch-shortage-after-fda-endorsement
- HHS. HHS Advances Women’s Health, Removes Misleading FDA Warnings on Hormone Replacement Therapy. November 10, 2025. https://www.hhs.gov/press-room/hhs-advances-womens-health-removes-misleading-fda-warnings-hormone-replacement-therapy.html
- Estrogen patches are in short supply as women seek menopause support. CNBC, June 26, 2026. https://www.cnbc.com/2026/06/26/estrogen-patches-are-in-short-supply-as-women-seek-menopause-support.html
- HHS to cut 10,000 staff in major restructuring. BioPharma Dive. https://www.biopharmadive.com/news/hhs-layoffs-restructuring-kennedy-fda-cms-trump/743694/
- ASHP Drug Shortage Detail: Estradiol Transdermal System. https://www.ashp.org/drug-shortages/current-shortages/drug-shortage-detail.aspx?id=1206
- FDA acknowledges estrogen patch shortage, says it’s working to increase supply. Stateline, September 16, 2026. https://stateline.org/2026/09/16/fda-acknowledges-estrogen-patch-shortage-says-its-working-to-increase-supply/
- FDA claims there’s no estrogen patch shortage as women struggle to get prescriptions filled. NBC News. https://www.nbcnews.com/health/womens-health/fda-estrogen-patch-shortage-hormone-therapy-alternatives-rcna344233
- FDA removes menopause hormone therapy black box warnings. Harvard Health. https://www.health.harvard.edu/womens-health/fda-removes-menopause-hormone-therapy-black-box-warnings